BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 03, 2002
 |  BioCentury  |  Product Development

Breathing some half-life into Cialis

A recent hiccup at the FDA took Cialis from Lilly Icos LLC out of a dead heat with Bayer AG's vardenafil to become the second phosphodiesterase-5 inhibitor to reach the U.S. market for erectile dysfunction. But data presented at the American Urological Association (AUA) meeting in Orlando may give Lilly Icos the marketing hook it needs to grab market share once it gets final approval.

Both Cialis tadalafil and vardenafil are oral selective PDE-5 inhibitors, like Viagra sildenafil from Pfizer Inc. (PFE, New York, N.Y.). According to Alexander Rosar, a spokesperson for Bayer (FSE:BAYG, BAY; Leverkusen, Germany), vardenafil is on schedule to be approved in the third quarter and launched this year.

By contrast, Lilly Icos last month received an approvable letter from FDA, which asked for additional clinical pharmacology data, and thus the partners will not be able to take Cialis to market until next year (see BioCentury, May 6).

But at AUA last week, the joint venture between Eli Lilly and Co. (LLY, Indianapolis, Ind.) and Icos Corp....

Read the full 875 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >